Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The example project in this lecture
- The complexity of the immune system
- A systems immunological approach to dissect ongoing immune responses
- How to use single cell technologies and systems immunology
- Impaired type I IFN activity and inflammatory responses
- Autoantibodies against type I IFNs
- What other factors may account for severe cases?
- The adaptive immune system reacting to SARS-CoV-2 over time
- Chronic presence of plasmablasts in peripheral blood during severe COVID-19
- 10x genomics technology
- Transcriptomic clusters of activated B cells in COVID-19 patients
- Activated B cells of severe COVID patients show no IFN-instruction later on
- Cytokines are targeting immunoglobulin switch recombination to distinct classes
- Antibody-isotypes report the cytokines driving the immune reaction
- Is it an immune reaction against SARS-CoV-2?
- IgA2 of COVID-19 patients is not specific for SARS-CoV-2 spike protein
- If not SARS-CoV-2, what are the antibodies targeting?
- None of the cloned BCRs recognize the SARS-CoV-2 spike or nucleoprotein
- Severe COVID-19: TGF-β chronic immune reaction
- Could TGF-β be to blame for delayed IFN response seen in severe COVID-19?
- Early peak of serum TGF-β during severe COVID-19
- A TGF-β response gene signature of NK cells is characteristic for severe COVID-19
- TGF-β response is specific to severe COVID-19 and limits antiviral function of NK cells (1)
- TGF-β response is specific to severe COVID-19 and limits antiviral function of NK cells (2)
- Antiviral function of NK cells can be restored by anti-TGF-β
- Which cells are expressing and responsible for the early peak of TGF-β
- Lung cells from deceased COVID-19 patients express increased levels of TGF-β1 (1)
- Lung cells from deceased COVID-19 patients express increased levels of TGF-β1 (2)
- How does SARS-CoV-2 induce or mimic TGF-β responses in infected cells?
- SARS-CoV-2 nucleoprotein (N) interacts with activated SMAD3
- SARS-CoV-2 factors which promote TGF-β
- Studying immune responses in severe COVID-19 at single cell level
- Induction of a TGF-β response and the delayed IFN response in patients with severe COVID-19
- Acknowledgements
Topics Covered
- Severe COVID-19
- Impaired type 1 interferon activity
- The adaptive immune system and COVID-19
- Chronic presence of plasmablasts
- 10x genomics technology
- Transcriptomic clusters
- IgA2
- IgG1
- IgM
- IgA1
- Spike protein and nucleoprotein
- TGF-β
Links
Series:
- The Immune System - Key Concepts and Questions
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Mashreghi, M. (2023, January 31). Studying immune responses “one cell at a time” [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/NWQQ7832.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Mir-Farzin Mashreghi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.